NYPRG-101 is under clinical development by Ceruvia Lifesciences and currently in Phase I for Alcohol Dependence. According to GlobalData, Phase I drugs for Alcohol Dependence does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the NYPRG-101 LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
NYPRG-101 overview
NYPRG-101 (BOL-148) is under development for the treatment of migraine, cluster headache, opioid use disorder, and alcohol use disorder. The drug candidate is a 2-bromo-D-lysergic acid diethylamide. It acts by targeting 5-hydroxytryptamine receptor 2A (5HT2A) receptor.
Ceruvia Lifesciences overview
Ceruvia Lifesciences is a clinical-stage biopharmaceutical company that carries out the research, development and commercialization of neuro transformational medicines to treat neurological and psychiatric disorders. The company pipeline products include NYPRG-101 (BOL-148) and SYNP-101 (synthetic psilocybin) for the treatment of migraine, headache disorder and alcohol use disorder. The company works in collaboration with Yale University, Usona Institute, The Heffter Research Institute, Clusterbusters and New York University (NYU). Ceruvia Lifesciences is headquartered in Greenwich, Connecticut, the US.
For a complete picture of NYPRG-101’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
